ARCH, Flagship, CRO fund in $30m Syros launch

Newly launched Syros Pharmaceuticals has completed a $30 million Series A venture financing with two blue chips VCs, and the corporate venture fund of a Chinese clinical research firm as investors.

More from Anticancer

More from Therapeutic Category